Finch Therapeutics Regains Rights to Two Takeda-Owned IBD Drugs

Following the termination of a multi-year collaboration with Takeda Pharmaceutical, Finch Therapeutics has regained the rights to two assets, FIN-524 and FIN-525, assessed for forms of inflammatory bowel disease.